Tilidine Hydrochloride/Naloxone

盐酸替立定/纳洛酮

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTilidine Hydrochloride/Naloxone
Drug Alias Name复方盐酸替利定复方盐酸替利定缓释片
ClassificationSmall molecules
Mechanisms of ActionOpioid receptors agonistsMu opioid receptor antagonists
TargetsOpioid receptorsMu opioid receptor
Therapy Area/IndicationsChronic PainCancer PainAcute Pain +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Tilidine Hydrochloride
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Lisheng Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Lisheng Pharmaceutical Group Co LtdSichuan Antibiotic Industry Research Institute Co LtdLangfang Branch Of Sinopharm Group Industrial Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic PainCancer PainAcute Pain +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A